Reuters logo
6 个月前
BRIEF-Daiichi Sankyo and ArQule's carcinoma drug failed in late-stage trial
2017年2月17日 / 上午11点14分 / 6 个月前

BRIEF-Daiichi Sankyo and ArQule's carcinoma drug failed in late-stage trial

Feb 17 (Reuters) - ArQule Inc-

* Daiichi Sankyo and Arqule announce the completion of the metiv-hcc phase 3 study of tivantinib in second-line treatment of met-overexpressing hepatocellular carcinoma

* Study of tivantinib in hepatocellular carcinoma (hcc) did not meet its primary endpoint of improving overall survival

* Primary endpoint of study is overall survival Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below